SeraNovo Appoints Michiel Van Speybroeck as Chief Development Officer

We are thrilled to announce the appointment of Michiel Van Speybroeck as our Chief Development Officer. 


Over the last 10 years, Michiel has held technical leadership positions in the pharmaceutical contract development and manufacturing industry. Most recently, he was Corporate Technology Officer at Ardena, where he was responsible for the technical integration of the company’s services and the management of cross-functional chemical-pharmaceutical development programs in support of early-phase clinical studies. Prior to that, he was Head of Formulation at Ardena. In this position, he was accountable for the company’s dosage form design and development strategy. Before joining Ardena, Michiel was R&D Director and subsequently Chief Scientific Officer at Formac Pharmaceuticals.


Read the full press release here.

This website uses cookies to track the usage of it.

More info